Is pulmonary hypertension a metabolic disease?
作者信息
Barnes Jarrod, Dweik Raed A
机构信息
1 Lerner Research Institute Cleveland Clinic Cleveland, Ohio and.
出版信息
Am J Respir Crit Care Med. 2014 Nov 1;190(9):973-5. doi: 10.1164/rccm.201409-1702ED.
Abstract
摘要
相似文献
1
Is pulmonary hypertension a metabolic disease?
Am J Respir Crit Care Med. 2014 Nov 1;190(9):973-5. doi: 10.1164/rccm.201409-1702ED.
2
The sphingosine kinase 1/sphingosine-1-phosphate pathway in pulmonary arterial hypertension.
Am J Respir Crit Care Med. 2014 Nov 1;190(9):1032-43. doi: 10.1164/rccm.201401-0121OC.
3
[Function and metabolism of the bioactive lipid molecule sphingosine 1-phosphate].
Tanpakushitsu Kakusan Koso. 2005 Sep;50(11):1443-8.
4
[Molecular diversity of sphingosine kinase].
Tanpakushitsu Kakusan Koso. 2002 Mar;47(4 Suppl):509-13.
5
[Role of S1P acting both inside and outside the cells].
Seikagaku. 2012 Feb;84(2):92-101.
6
7
Sphingosine kinase regulation and cardioprotection.
Cardiovasc Res. 2009 May 1;82(2):184-92. doi: 10.1093/cvr/cvn309. Epub 2008 Nov 18.
8
[Sphingosine 1-phosphate in yeast].
Tanpakushitsu Kakusan Koso. 2002 Mar;47(4 Suppl):431-7.
9
Export and functions of sphingosine-1-phosphate.
Biochim Biophys Acta. 2009 Jul;1791(7):692-6. doi: 10.1016/j.bbalip.2009.02.011. Epub 2009 Mar 4.
10
Immunology. The sources of a lipid conundrum.
Science. 2007 Apr 13;316(5822):208-10. doi: 10.1126/science.1142239.
引用本文的文献
1
Plasma metabolomic profile in chronic thromboembolic pulmonary hypertension.
Pulm Circ. 2020 Feb 4;10(1):2045894019890553. doi: 10.1177/2045894019890553. eCollection 2020 Jan-Mar.
2
Novel methods in pulmonary hypertension phenotyping in the age of precision medicine (2015 Grover Conference series).
Pulm Circ. 2016 Dec;6(4):439-447. doi: 10.1086/688847.
3
Bone Morphogenic Protein Type 2 Receptor Mutation-Independent Mechanisms of Disrupted Bone Morphogenetic Protein Signaling in Idiopathic Pulmonary Arterial Hypertension.
Am J Respir Cell Mol Biol. 2016 Oct;55(4):564-575. doi: 10.1165/rcmb.2015-0402OC.
4
Sildenafil reduces signs of oxidative stress in pulmonary arterial hypertension: Evaluation by fatty acid composition, level of hydroxynonenal and heart rate variability.
Redox Biol. 2016 Apr;7:48-57. doi: 10.1016/j.redox.2015.11.009. Epub 2015 Nov 22.
本文引用的文献
1
The sphingosine kinase 1/sphingosine-1-phosphate pathway in pulmonary arterial hypertension.
Am J Respir Crit Care Med. 2014 Nov 1;190(9):1032-43. doi: 10.1164/rccm.201401-0121OC.
2
Accumulation of extracellular hyaluronan by hyaluronan synthase 3 promotes tumor growth and modulates the pancreatic cancer microenvironment.
Biomed Res Int. 2014;2014:817613. doi: 10.1155/2014/817613. Epub 2014 Jul 24.
3
Leptin deficiency recapitulates the histological features of pulmonary arterial hypertension in mice.
Int J Clin Exp Pathol. 2014 Apr 15;7(5):1935-46. eCollection 2014.
4
An official American Thoracic Society Statement: pulmonary hypertension phenotypes.
Am J Respir Crit Care Med. 2014 Feb 1;189(3):345-55. doi: 10.1164/rccm.201311-1954ST.
5
Importance of sphingosine kinase (SphK) as a target in developing cancer therapeutics and recent developments in the synthesis of novel SphK inhibitors.
J Med Chem. 2014 Jul 10;57(13):5509-24. doi: 10.1021/jm4011687. Epub 2014 Feb 11.
6
Novel and emerging therapies for pulmonary hypertension.
Am J Respir Crit Care Med. 2014 Feb 15;189(4):394-400. doi: 10.1164/rccm.201308-1543PP.
7
8
Pathogenesis of pulmonary arterial hypertension: lessons from cancer.
Eur Respir Rev. 2013 Dec;22(130):543-51. doi: 10.1183/09059180.00007513.
9
Adiponectin levels are elevated in patients with pulmonary arterial hypertension.
Clin Cardiol. 2014 Jan;37(1):21-5. doi: 10.1002/clc.22210. Epub 2013 Oct 1.
10
O-GlcNAc in cancer biology.
Amino Acids. 2013 Oct;45(4):719-33. doi: 10.1007/s00726-013-1543-8. Epub 2013 Jul 9.
Zotero 插件